High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects
Paul Goepfert(University of Maryland, Baltimore), David C. Montefiori(Duke University), Mary Allen(National Institutes of Health), Jonathan D. Fuchs, Paul Spearman(Cincinnati Children's Hospital Medical Center), Georgia D. Tomaras(National Institutes of Health), Guido Ferrari(Duke University), Lawrence Corey(Fred Hutch Cancer Center), Beryl A. Koblin(New York Blood Center), Sharon E. Frey(St. Louis VA Medical Center), M. Juliana McElrath(Fred Hutch Cancer Center), Lindsey R. Baden(Brigham and Women's Hospital), Helen Horton(New York Blood Center), Michael C. Keefer(University of Rochester Medical Center), William A. Blattner(Unknown), Sanjay Gurunathan(GTx (United States)), Ya‐Lin Chiu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 65
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k